Congresso SONO 2022

Dados do Trabalho


Título

Effects of CPAP on Central and Peripheral Blood Pressure in Patients with Uncontrolled Hypertension and Obstructive Sleep Apnea: Final Analysis of the multicenter MORPHEOS trial.

Introdução

The impact of obstructive sleep apnea (OSA) treatment with continuous positive airway pressure (CPAP) on central and peripheral blood pressure (BP) is not well established in patients with uncontrolled hypertension (HTN).

Objetivo

Evaluate the impact of OSA treatment with CPAP on central BP, office BP and 24-hours ambulatory BP monitoring (ABPM).

Métodos

The MORPHEOS is a multicenter (n=6) randomized controlled trial designed to evaluate the BP lowering effects of treatment with CPAP or placebo nasal dilator strips (NDS) for 6-months in adult patients with uncontrolled HTN and moderate-to-severe OSA. Patients using at least one anti-hypertensive medication (AHM) were included. Uncontrolled HTN was confirmed by at least one abnormal parameter in the 24-hours ABPM and ≥80% medication adherence evaluated by pill counting after the run-in period (4 weeks). OSA was defined by an apnea-hypopnea index ≥15/h. The co-primary endpoints are brachial BP (office and ABPM) and central BP. Secondary outcomes include hypertension-mediated organ damage. Visits occur once a week in the first month and once o month thereafter.

Resultados

One-hundred fourth-five patients with uncontrolled hypertension (median 3 [1.8;4.0] AHM, baseline values of office systolic and diastolic BP: 153±17 and 93±12mmHg, respectively) and OSA were randomized to NDS (n=72) and CPAP group (n=73). Due to COVID-19 pandemic and refusals to repeat exams, 22 randomized patients did not complete the study. Baseline clinical and polysomnographic variables were similar between the groups. Compared to NDS, CPAP promoted a greater reduction in SBP and DBP at 6 months (Δ Delta SBP: DNS -4±17 vs. CPAP -10±16mmHg, p=0.027; Δ DBP: NDS -1.27±10 vs. CPAP -7±12mmHg, p=0.004). Regarding central BP, CPAP promoted a greater reduction in central SBP and DBP but did reach statistical significance at 6 months only for DBP (Δ central SBP: NDS -6±19 vs. CPAP -10±17mmHg, p=0.09; Δ central DBP: DNS -3±13 vs. CPAP -6±9mmHg, p=0.006). 24-hours ABPM analysis revealed no differences in BP for the comparisons of NDS and CPAP but CPAP reduced nighttime heart rate as compared to NDS.

Conclusões

In patients with uncontrolled HTN and OSA under regular AHM, CPAP was effective in reducing office SBP, DBP and central DBP; but have no significant effects on ABPM parameters as compared to placebo.

Palavras -chave

hypertension, obstructive sleep apnea, continuous positive airway pressure

Área

Área Clínica

Instituições

1. Sleep Laboratory, Pulmonary Division, Heart Institute (InCor), University of Sao Paulo Medical School, Sao Paulo, Brazil. - São Paulo - Brasil, 2. Sleep and Heart Laboratory, Pronto Socorro Cardiologic de Pernambuco (PROCAPE), University of Pernambuco, Recife, Brazil. - Pernambuco - Brasil, 3. Interdisciplinary Sleep Research Laboratory, Hospital de Clínicas de Porto Alegre (LIPES-HCPA), Porto Alegre, RS, Brazil. - Rio Grande do Sul - Brasil, 4. University of São Paulo, Ribeirão Preto School of Medicine, Ribeirão Preto, Brazil. - São Paulo - Brasil, 5. Hypertension Unit, Heart Institute (InCor), University of Sao Paulo Medical School, Sao Paulo, Brazil. - São Paulo - Brasil, 6. Division of Cardiology, Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil. - São Paulo - Brasil

Autores

Geraldo Lorenzi-Filho, Fernanda Carolina Silva Guimarães Cruz, Daniel Barboza Cava Queiróz, Rodrigo P Pedrosa, Tarcya L. G. Couto Patriota, Denis Martinez, Geruza A Silva, Luiz Aparecido Bortolotto, Flávio Fuchs, Luciano Ferreira Drager